PellePharm

PellePharm is a biotechnology company committed to targeting rare dermatologic diseases, including Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), at their source. Founded by world leaders in hedgehog signaling, PellePharm is working to improve the quality of life for those suffering from regular, debilitating surgeries by providing an easy-to-use topical solution that eliminates this need and provides an overall better quality of life. The standard of care for these diseases is surgery. In particular, people with severe Gorlin Syndrome may have as many as 30 surgeries per year, which can be repetitive and scarring. PellePharm’s patidegib gel has shown early promise in a phase 2 clinical study for the mitigation of the BCC tumors in Gorlin Syndrome by blocking the disease at its source within the hedgehog signaling pathway. Because oral formulations for this treatment typically have serious systemic side effects which cause many patients to discontinue treatment, patidegib is formulated as a topical gel to reduce its side effect profile due to its minimal systemic exposure. PellePharm is located in San Francisco, California. For more information about PellePharm, please visit us at www.pellepharm.com.